MediCrops® AG

MediCrops® Group is a pioneering Swiss healthcare venture redefining the pharmaceutical standard of care. As a fully integrated ecosystem, we combine telemedicine, digital health platforms, pharmaceutical compounding, and licensed distribution to deliver safe, personalized, and scalable treatments for complex medical conditions. Our core focus: prescription-based therapies with a strong specialization in cannabinoid medicine, produced under the highest pharmaceutical quality standards. With a state-of-the-art infrastructure and a growing network of medical experts, MediCrops® empowers physicians and patients with access to individualized treatment options — anytime, anywhere. We are building Europe’s next-generation digital health leader — driven by technology, regulated precision, and patient impact.